Improving T cell therapy for cancer

Expert Opinion on Biological Therapy

Volumn 6, Issue 3, 2006, Pages 215-229

  Foster, Aaron E ^b   Rooney, Cliona M ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b NONE

Author keywords

Adoptive immunotherapy; Cancer; Gene therapy; T lymphocytes

Indexed keywords

B7 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; FAS LIGAND; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROSTAGLANDIN E2; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VIRUS ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CANCER; CELL KILLING; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DNA MODIFICATION; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNOGENICITY; LYMPHOPROLIFERATIVE DISEASE; MAJOR HISTOCOMPATIBILITY COMPLEX; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION; TARGET CELL; TUMOR CELL; VACCINATION;

ANIMALS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 4;

EID: 33644747233     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.6.3.215     Document Type: Review

References (146)

1. RIDDELL SR, WATANABE KS, GOODRICH JM et al.: Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science (1992) 257(5067):238-241. Demonstrated the feasibility and efficacy of adoptive transfer with CMV-specific T cell clones.
2. WALTER EA, GREENBERG PD, GILBERT MJ et al.: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med. (1995) 333(16):1038-1044. Demonstrated the feasibility and efficacy of adoptive transfer with CMV-specific T cell clones.
3. ROONEY CM, SMITH CA, NG CY et al.: Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet (1995) 345(8941):9-13. Demonstrated the feasibility and efficacy of adoptive transfer of polyclonal EBV-specific T cell lines.
4. ROONEY CM, SMITH CA, NG CY et al.: Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood (1998) 92(5):1549-1555.
5. KHANNA R, BELL S, SHERRITT M et al.: Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease. Proc. Natl. Acad. Sci. USA (1999) 96(18):10391-10396. Clinical trial for using EBV-specific cytotoxic T cells for the treatment of EBV-LPD.
6. HESLOP HE, NG CY, LI C et al.: Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nat. Med. (1996) 2(5):551-555. Use of gene marking to track in vivo persistence and expansion of transfused EBV-specific T cell lines.
7. HESLOP HE, BRENNER MK, ROONEY CM: Donor T cells to treat EBV-associated lymphoma. N. Engl. J. Med. (1994) 331(10):679-680.
8. PAPADOPOULOS EB, LADANYI M, EMANUEL D et al.: Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N. Engl. J. Med. (1994) 330(17):1185-1191.
9. WANG L, GOILLOT E, TEPPER RI: IL-10 inhibits alloreactive cytotoxic T lymphocyte generation in vivo. Cell. Immunol. (1994) 159(2):152-169.
10. SUZUKI T, TAHARA H, NARULA S et al.: Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumours. J. Exp. Med. (1995) 182(2):477-486.
11. NEWCOM SR, KADIN ME, ANSARI AA, DIEHL V: L-428 nodular sclerosing Hodgkin's cell secretes a unique transforming growth factor-beta active at physiologic pH. J. Clin. Invest. (1988) 82(6):1915-1921.
12. NEWCOM SR, GU L: Transforming growth factor beta 1 messenger RNA in Reed-Sternberg cells in nodular sclerosing Hodgkin's disease. J. Clin. Pathol. (1995) 48(2):160-163.
13. MARSHALL NA, CHRISTIE LE, MUNRO LR et al.: Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood (2004) 103(5):1755-1762.
14. GILBOA E: How tumours escape immune destruction and what we can do about it. Cancer Immunol. Immunother. (1999) 48(7):382-385.
15. BOLLARD CM, AGUILAR L, STRAATHOF KC et al.: Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J. Exp. Med. (2004) 200(12):1623-1633. Clinical trial using EBV-specific T cells for the treatment of HD.
16. STRAATHOF KC, BOLLARD CM, POPAT U et al.: Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood (2005) 105(5):1898-1904. Clinical trial using EBV-specific T cells for the treatment of NPC.
17. BANCHEREAU J, BRIERE F, CAUX C et al.: Immunobiology of dendritic cells. Annu. Rev. Immunol. (2000) 18:767-811.
18. LUTZ MB, SCHULER G: Immature, semimature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol. (2002) 23(9):445-449.
19. JONULEIT H, SCHMITT E, STEINBRINK K, ENK AH: Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol. (2001) 22(7):394-400.
20. VONDERHEIDE RH, HAHN WC, SCHULTZE JL, NADLER LM: The telomerase catalytic subunit is a widely expressed tumour-associated antigen recognized by cytotoxic T lymphocytes. Immunity (1999) 10(6):673-679.
21. SCHULTZE JL, MICHALAK S, SEAMON MJ et al.: CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J. Clin. Invest. (1997) 100(11):2757-2765.
22. OELKE M, MAUS MV, DIDIANO D et al.: Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig-coated artificial antigen-presenting cells. Nat. Med. (2003) 9(5):619-624.
23. OOSTEN LE, BLOKLAND E, VAN HALTEREN AG et al.: Artificial antigen-presenting constructs efficiently stimulate minor histocompatibility antigen-specific cytotoxic T lymphocytes. Blood (2004) 104(1):224-226.
24. SCHILBACH K, KERST G, WALTER S et al.: Cytotoxic minor histocompatibility antigen HA-1-specific CD8+ effector memory T cells: artificial APCs pave the way for clinical application by potent primary in vitro induction. Blood (2005) 106(1):144-149.
25. SALLUSTO F, GEGINAT J, LANZAVECCHIA A: Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. (2004) 22:745-763. One of a series of papers describing functional and phenotypic differences between memory and naïve T cells.
26. APPAY V, ROWLAND-JONES SL: Lessons from the study of T-cell differentiation in persistent human virus infection. Semin. Immunol. (2004) 16(3):205-212. One of a series of papers describing functional and phenotypic differences between memory and naïve T cells.
27. WHERRY EJ, TEICHGRABER V, BECKER TC et al.: Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat. Immunol. (2003) 4(3):225-234. One of a series of papers describing functional and phenotypic differences between memory and naïve T cells.
28. GATTINONI L, KLEBANOFF CA, PALMER DC et al.: Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumour efficacy of adoptively transferred CD8(+) T cells. J. Clin. Invest. (2005) 115(6):1616-1626. Murine study demonstrating that T cell differentiation is crucial to persistence and antitumour effect.
29. WATANABE N, KAMACHI Y, KOYAMA N et al.: Expansion of human CMV-specific cytotoxic T lymphocytes to a clinical scale: a simple culture system using tetrameric HLA-peptide complexes. Cytotherapy (2004) 6(5):514-522.
30. BISSINGER AL, RAUSER G, HEBART H et al.: Isolation and expansion of human cytomegalovirus- specific cytotoxic T lymphocytes using interferon-gamma secretion assay. Exp. Hematol. (2002) 30(10):1178-1184.
31. KUPPERS R: B cells under influence: transformation of B cells by Epstein-Barr virus. Nat. Rev. Immunol. (2003) 3(10):801-812.
32. VAN DEN BERG A, VISSER L, POPPEMA S: High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. Am. J. Pathol. (1999) 154(6):1685-1691.
33. POPPEMA S, POTTERS M, VISSER L, VAN DEN BERG AM: Immune escape mechanisms in Hodgkin's disease. Ann. Oncol. (1998) 9(Suppl. 5):S21-S24.
34. CHEN W, JIN W, HARDEGEN N et al.: Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. (2003) 198(12):1875-1886. Provides evidence that tumour-secreted factors can induce Treg suppressing cellular-mediated killing.
35. FANTINI MC, BECKER C, MONTELEONE G et al.: Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol. (2004) 172(9):5149-5153. Provides evidence that tumour-secreted factors can induce Treg suppressing cellular-mediated killing.
36. ARTEAGA CL, HURD SD, WINNIER AR et al.: Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumourigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumour cell/host TGF-beta interactions in human breast cancer progression. J. Clin. Invest. (1993) 92(6):2569-2576.
37. BANDYOPADHYAY A, LOPEZ-CASILLAS F, MALIK SN et al.: Antitumour activity of a recombinant soluble betaglycan in human breast cancer xenograft. Cancer Res. (2002) 62(16):4690-4695.
38. STANDER M, NAUMANN U, DUMITRESCU L et al.: Decorin gene transfer-mediated suppression of TGF-beta synthesis abrogates experimental malignant glioma growth in vivo. Gene Ther. (1998) 5(9):1187-1194.
39. WON J, KIM H, PARK EJ et al.: Tumourigenicity of mouse thymoma is suppressed by soluble Type II transforming growth factor beta receptor therapy. Cancer Res. (1999) 59(6):1273-1277.
40. SUZUKI E, KAPOOR V, CHEUNG HK et al.: Soluble Type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumour growth by augmenting host antitumour immunity. Clin. Cancer Res. (2004) 10(17):5907-5918.
41. GORELIK L, FLAVELL RA: Immune-mediated eradication of tumours through the blockade of transforming growth factor-beta signaling in T cells. Nat. Med. (2001) 7(10):1118-1122.
42. BOLLARD CM, ROSSIG C, CALONGE MJ et al.: Adapting a transforming growth factor beta-related tumour protection strategy to enhance antitumour immunity. Blood (2002) 99(9):3179-3187.
43. ZHANG Q, YANG X, PINS M et al.: Adoptive transfer of tumour-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res. (2005) 65(5):1761-1769.
44. KOBAYASHI M, FITZ L, RYAN M et al.: Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. (1989) 170(3):827-845.
45. STERN AS, PODLASKI FJ, HULMES JD et al.: Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc. Natl. Acad. Sci. USA (1990) 87(17):6808-6812.
46. YOUNES A, PRO B, ROBERTSON MJ et al.: Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin. Cancer Res. (2004) 10(16):5432-5438.
47. VAN HERPEN CM, HUIJBENS R, LOOMAN M et al.: Pharmacokinetics and immunological aspects of a Phase Ib study with intratumoural administration of recombinant human interleukin-12 in patients with head and neck squamous cell carcinoma: a decrease of T-bet in peripheral blood mononuclear cells. Clin. Cancer Res. (2003) 9(8):2950-2956.
48. GOLLOB JA, VEENSTRA KG, PARKER RA et al.: Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J. Clin. Oncol. (2003) 21(13):2564-2573.
49. PORTIELJE JE, KRUIT WH, SCHULER M et al.: Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin. Cancer Res. (1999) 5(12):3983-3989.
50. MOTZER RJ, RAKHIT A, SCHWARTZ LH et al.: Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clin. Cancer Res. (1998) 4(5):1183-1191.
51. ATKINS MB, ROBERTSON MJ, GORDON M et al.: Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. (1997) 3(3):409-417.
52. LEONARD JP, SHERMAN ML, FISHER GL et al.: Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood (1997) 90(7):2541-2548.
53. ANDERSON R, MACDONALD I, CORBETT T et al.: Construction and biological characterization of an interleukin-12 fusion protein (Flexi-12): delivery to acute myeloid leukemic blasts using adeno-associated virus. Hum. Gene Ther. (1997) 8(9):1125-1135.
54. WAGNER HJ, BOLLARD CM, VIGOUROUX S et al.: A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumour environment using tumour antigen-specific T cells. Cancer Gene Ther. (2004) 11(2):81-91.
55. O'CONNELL J, O'SULLIVAN GC, COLLINS JK, SHANAHAN F: The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. (1996) 184(3):1075-1082. One of a series of papers that describes a tumour immune escape mechanism that operates through Fas/FasL.
56. STRAND S, HOFMANN WJ, HUG H et al.: Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumour cells-a mechanism of immune evasion? Nat. Med. (1996) 2(12):1361-1366. One of a series of papers that describes a tumour immune escape mechanism that operates through Fas/FasL.
57. HAHNE M, RIMOLDI D, SCHROTER M et al.: Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumour immune escape. Science (1996) 274(5291):1363-1366. One of a series of papers that describes a tumour immune escape mechanism that operates through Fas/FasL.
58. TSAI ST, FANG SY, JIN YT, SU IJ, YANG BC: Analysis of the expression of Fas-L in nasopharyngeal carcinoma tissues. Oral Oncol. (1999) 35(4):421-424.
59. VERBEKE CS, WENTHE U, GROBHOLZ R, ZENTGRAF H: Fas ligand expression in Hodgkin lymphoma. Am. J. Surg. Pathol. (2001) 25(3):388-394.
60. OHSHIMA K, MUTA K, NAKASHIMA M et al.: Expression of human tumour-associated antigen RCAS1 in Reed-Sternberg cells in association with Epstein-Barr virus infection: a potential mechanism of immune evasion. Int. J. Cancer (2001) 93(1):91-96.
61. DOTTI G, SAVOLDO B, PULE M et al.: Human cytotoxic T-lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood (2005) 105(12):4677-4684.
62. EATON D, GILHAM DE, O'NEILL A, HAWKINS RE: Retroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions. Gene Ther. (2002) 9(8):527-535.
63. YEE C, THOMPSON JA, ROCHE P et al.: Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J. Exp. Med. (2000) 192(11):1637-1644. Demonstrated that antigen-specific T cells targeting melanoma kill both MART-1-expressing melanoma cells as well as normal MART-1-expressing tissue.
64. DUDLEY ME, WUNDERLICH JR, ROBBINS PF et al.: Cancer regression and autoimmunity in patients after clonal repopulation with antitumour lymphocytes. Science (2002) 298(5594):850-854. Seminal paper describing the use of lymphodepletion to increase the efficacy and in vivo expansion of adoptively transferred melanoma-specific T cells.
65. ROSENBERG SA, SPIESS P, LAFRENIERE R: A new approach to the adoptive immunotherapy of cancer with tumour-infiltrating lymphocytes. Science (1986) 233(4770):1318-1321.
66. OVERWIJK WW, THEORET MR, FINKELSTEIN SE et al.: Tumour regression and autoimmunity after reversal of a functionally tolerant state of self reactive CD8+ T cells. J. Exp. Med. (2003) 198(4):569-580.
67. LIU K, ROSENBERG SA: Interleukin-2-independent proliferation of human melanoma-reactive T lymphocytes transduced with an exogenous IL-2 gene is stimulation dependent. J. Immunother. (2003) 26(3):190-201.
68. SPRENT J: Burnet oration. T-cell survival and the role of cytokines. Immunol. Cell Biol. (2001) 79(3):199-206.
69. LORD JD, MCINTOSH BC, GREENBERG PD, NELSON BH: The IL-2 receptor promotes proliferation, bcl-2 and bcl-x induction, but not cell viability through the adapter molecule Shc. J. Immunol. (1998) 161(9):4627-4633.
70. SMITH KA: Interleukin-2: inception, impact, and implications. Science (1988) 240(4856):1169-1176.
71. CHARO J, FINKELSTEIN SE, GREWAL N et al.: Bcl-2 overexpression enhances tumour-specific T-cell survival. Cancer Res. (2005) 65(5):2001-2008.
72. HOOIJBERG E, RUIZENDAAL JJ, SNIJDERS PJ et al.: Immortalization of human CD8+ T cell clones by ectopic expression of telomerase reverse transcriptase. J. Immunol. (2000) 165(8):4239-4245.
73. LUITEN RM, PENE J, YSSEL H, SPITS H: Ectopic hTERT expression extends the life span of human CD4+ helper and regulatory T-cell clones and confers resistance to oxidative stress-induced apoptosis. Blood (2003) 101(11):4512-4519.
74. ROTH A, YSSEL H, PENE J et al.: Telomerase levels control the lifespan of human T lymphocytes. Blood (2003) 102(3):849-857.
75. VERRA NC, JORRITSMA A, WEIJER K et al.: Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice. Cancer Res. (2004) 64(6):2153-2161.
76. ROTH A, BAERLOCHER GM, SCHERTZER M et al.: Telomere loss, senescence and genetic instability in CD4+ T lymphocytes overexpressing hTERT. Blood (2005) 106(1):43-50.
77. PEGGS KS, MACKINNON S: Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy. Hum. Immunol. (2004) 65(5):550-557.
78. COMBADIERE B, BOISSONNAS A, CARCELAIN G et al.: Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans. J. Exp. Med. (2004) 199(11):1585-1593.
79. COHEN J: Bioterrorism. Smallpox vaccinations: how much protection remains? Science (2001) 294(5544):985.
80. ESHHAR Z: Tumour-specific T-bodies: towards clinical application. Cancer Immunol. Immunother. (1997) 45(3-4):131-136.
81. PULE M, FINNEY H, LAWSON A: Artificial T-cell receptors. Cytotherapy (2003) 5(3):211-226.
82. ESHHAR Z, WAKS T, GROSS G, SCHINDLER DG: Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA (1993) 90(2):720-724. Seminal paper describing T bodies for redirecting T cell specificity.
83. WEIJTENS ME, WILLEMSEN RA, HART EH, BOLHUIS RL: A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes. Gene Ther. (1998) 5(9):1195-1203.
84. MORITZ D, WELS W, MATTERN J, GRONER B: Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumour cells. Proc. Natl. Acad. Sci. USA (1994) 91(10):4318-4322.
85. MORITZ D, GRONER B: A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity. Gene Ther. (1995) 2(8):539-546.
86. ALTENSCHMIDT U, KLUNDT E, GRONER B: Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumour regression. J. Immunol. (1997) 159(11):5509-5515.
87. HAYNES NM, TRAPANI JA, TENG MW et al.: Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumours. Blood (2002) 100(9):3155-3163.
88. HOMBACH A, SCHNEIDER C, SENT D et al.: An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen-positive tumour cells. Int. J. Cancer (2000) 88(1):115-120.
89. ROSSIG C, BOLLARD CM, NUCHTERN JG, ROONEY CM, BRENNER MK: Epstein-Barr virus-specific human T lymphocytes expressing antitumour chimeric T-cell receptors: potential for improved immunotherapy. Blood (2002) 99(6):2009-2016.
90. MAHER J, BRENTJENS RJ, GUNSET G, RIVIERE I, SADELAIN M: Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat. Biotechnol. (2002) 20(1):70-75.
91. GONG MC, LATOUCHE JB, KRAUSE A et al.: Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia (1999) 1(2):123-127.
92. KERSHAW MH, DARCY PK, TRAPANI JA, SMYTH MJ: The use of chimeric human Fc(epsilon) receptor I to redirect cytotoxic T lymphocytes to tumours. J. Leukoc. Biol. (1996) 60(6):721-728.
93. ALVAREZ-VALLINA L, HAWKINS RE: Antigen-specific targeting of CD28-mediated T cell co-stimulation using chimeric single-chain antibody variable fragment-CD28 receptors. Eur. J. Immunol. (1996) 26(10):2304-2309.
94. FINNEY HM, LAWSON AD, BEBBINGTON CR, WEIR AN: Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J. Immunol. (1998) 161(6):2791-2797.
95. KRAUSE A, GUO HF, LATOUCHE JB et al.: Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J. Exp. Med. (1998) 188(4):619-626.
96. BEECHAM EJ, MA Q, RIPLEY R, JUNGHANS RP: Coupling CD28 co-stimulation to immunoglobulin T-cell receptor molecules: the dynamics of T-cell proliferation and death. J. Immunother. (2000) 23(6):631-642.
97. HOMBACH A, WIECZARKOWIECZ A, MARQUARDT T et al.: Tumour-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J. Immunol. (2001) 167(11):6123-6131.
98. WILLEMSEN RA, DEBETS R, CHAMES P, BOLHUIS RL: Genetic engineering of T cell specificity for immunotherapy of cancer. Hum. Immunol. (2003) 64(1):56-68.
99. PULE MA, STRAATHOF KC, DOTTI G et al.: A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol. Ther. (2005) 12(5):933-941.
100. DEMBIC Z, HAAS W, WEISS S et al.: Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature (1986) 320(6059):232-238. First paper to describe the transfer of heterologous TCRs to redirect T cell specificity.
101. SHILYANSKY J, NISHIMURA MI, YANNELLI JR et al.: T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumour-infiltrating lymphocyte lines. Proc. Natl. Acad. Sci. USA (1994) 91(7):2829-2833.
102. CALOGERO A, HOSPERS GA, KRUSE KM et al.: Retargeting of a T cell line by anti MAGE-3/HLA-A2 alpha beta TCR gene transfer. Anticancer Res. (2000) 20(3A):1793-1799.
103. COOPER LJ, KALOS M, LEWINSOHN DA, RIDDELL SR, GREENBERG PD: Transfer of specificity for human immunodeficiency virus Type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J. Virol. (2000) 74(17):8207-8212.
104. ORENTAS RJ, ROSKOPF SJ, NOLAN GP, NISHIMURA MI: Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide. Clin. Immunol. (2001) 98(2):220-228.
105. TSUJI T, YASUKAWA M, MATSUZAKI J et al.: Generation of human tumour-specific, HLA class I-restricted Th1 and Tc1 cells by cell engineering with tumour peptide-specific T cell receptor genes. Blood (2005) 106(2):470-476.
106. HACEIN-BEY-ABINA S, VON KALLE C, SCHMIDT M et al.: A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. (2003) 348(3):255-256. Describes oncogenesis by retroviral insertions in X-linked SCID patients.
107. ROSENBERG SA, AEBERSOLD P, CORNETTA K et al.: Gene transfer into humans-immunotherapy of patients with advanced melanoma, using tumour-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med. (1990) 323(9):570-578. Analysis of a series of patients receiving gene-modified T cells shows no evidence of lymphoproliferation.
108. BONINI C, FERRARI G, VERZELETTI S et al.: HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science (1997) 276(5319):1719-1724. Demonstrates effective elimination of donor-derived lymphocytes using the HSV-TK suicide gene.
109. RIDDELL SR, ELLIOTT M, LEWINSOHN DA et al.: T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat. Med. (1996) 2(2):216-223.
110. SPENCER DM, BELSHAW PJ, CHEN L et al.: Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization. Curr. Biol. (1996) 6(7):839-847.
111. THOMIS DC, MARKTEL S, BONINI C et al.: A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood (2001) 97(5):1249-1257.
112. STRAATHOF KC, PULE MA, YOTNDA P et al.: An inducible caspase 9 safety switch for T-cell therapy. Blood (2005) 105(11):4247-4254.
113. FAN L, FREEMAN KW, KHAN T, PHAM E, SPENCER DM: Improved artificial death switches based on caspases and FADD. Hum. Gene Ther. (1999) 10(14):2273-2285.
114. DUDLEY ME, WUNDERLICH J, NISHIMURA MI et al.: Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J. Immunother. (2001) 24(4):363-373.
115. DUDLEY ME, WUNDERLICH JR, YANG JC et al.: A Phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumour antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother. (2002) 25(3):243-251.
116. PRLIC M, LEFRANCOIS L, JAMESON SC: Multiple choices: regulation of memory CD8 T cell generation and homeostasis by interleukin (IL)-7 and IL-15. J. Exp. Med. (2002) 195(12):F49-F52.
117. TAN JT, ERNST B, KIEPER WC et al.: Interleukin (IL)-15 and IL-7 jointly regulate homeostatic proliferation of memory phenotype CD8+ cells but are not required for memory phenotype CD4+ cells. J. Exp. Med. (2002) 195(12):1523-1532.
118. GOLDRATH AW, BOGATZKI LY, BEVAN MJ: Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J. Exp. Med. (2000) 192(4):557-564. One of a series of papers showing the effects of homeostatic factors on the proliferation, differentiation and function of T cells.
119. BELL EB, SPARSHOTT SM: The peripheral T-cell pool: regulation by non-antigen induced proliferation? Semin. Immunol. (1997) 9(6):347-353.
120. DUMMER W, NIETHAMMER AG, BACCALA R et al.: T cell homeostatic proliferation elicits effective antitumour autoimmunity. J. Clin. Invest. (2002) 110(2):185-192. One of a series of papers showing the effects of homeostatic factors on the proliferation, differentiation and function of T cells.
121. SAKAGUCHI S: Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. (2004) 22:531-562.
122. PICCIRILLO CA, SHEVACH EM: Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin. Immunol. (2004) 16(2):81-88.
123. + Tregs improves antitumour immunity.
124. WANG HY, LEE DA, PENG G et al.: Tumour-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity (2004) 20(1):107-118.
125. JAVIA LR, ROSENBERG SA: CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J. Immunother. (2003) 26(1):85-93.
126. CURIEL TJ, COUKOS G, ZOU L et al.: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. (2004) 10(9):942-949.
127. ICHIHARA F, KONO K, TAKAHASHI A et al.: Increased populations of regulatory T cells in peripheral blood and tumour-infiltrating lymphocytes in patients with gastric and esophageal cancers. Clin. Cancer Res. (2003) 9(12):4404-4408.
128. PHAN GQ, YANG JC, SHERRY RM et al.: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA (2003) 100(14):8372-8377.
129. DURAISWAMY J, SHERRITT M, THOMSON S et al.: Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Blood (2003) 101(8):3150-3156.
130. + NPC.
131. TAYLOR GS, HAIGH TA, GUDGEON NH et al.: Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma. J. Virol. (2004) 78(2):768-778.
132. COMOLI P, LABIRIO M, BASSO S et al.: Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication. Blood (2002) 99(7):2592-2598. Clinical trial using EBV-specific T cells for the treatment of LPD.
133. CHUA D, HUANG J, ZHENG B et al.: Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma. Int. J. Cancer (2001) 94(1):73-80. Clinical trial using EBV-specific T cells for the treatment of NPC.
134. COMOLI P, DE PALMA R, SIENA S et al.: Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumour activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma. Ann. Oncol. (2004) 15(1):113-117. Clinical trial using EBV-specific T cells for the treatment of NPC.
135. ROSKROW MA, SUZUKI N, GAN Y et al.: Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood (1998) 91(8):2925-2934. Clinical trial using EBV-specific T cells for the treatment of HD.
136. LUCAS KG, SALZMAN D, GARCIA A, SUN Q: Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease. Cancer (2004) 100(9):1892-1901. Clinical trial using EBV-specific T cells for the treatment of HD.
137. LAPORT GG, LEVINE BL, STADTMAUER EA et al.: Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. Blood (2003) 102(6):2004-2013.
138. YEE C, THOMPSON JA, BYRD D et al.: Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumour effect of transferred T cells. Proc. Natl. Acad. Sci. USA (2002) 99(25):16168-16173. Clinical trial demonstrating the in vivo persistence and antitumour function of melanoma-specific T cells. These data also showed immune escape tumour variants by antigen loss in response to antigen-specific T cell clones.
139. MEIDENBAUER N, MARIENHAGEN J, LAUMER M et al.: Survival and tumour localization of adoptively transferred Melan-A-specific T cells in melanoma patients. J. Immunol. (2003) 170(4):2161-2169.
140. MITCHELL MS, DARRAH D, YEUNG D et al.: Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J. Clin. Oncol. (2002) 20(4):1075-1086. Clinical trial of melanoma-specific T cells for the treatment of tyrosinase-positive melanoma.
141. VISONNEAU S, CESANO A, PORTER DL et al.: Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer. Clin. Cancer Res. (2000) 6(5):1744-1754.
142. LUM LG, LEFEVER AV, TREISMAN JS, GARLIE NK, HANSON JP JR: Immune modulation in cancer patients after adoptive transfer of anti-CD3/anti-CD28- costimulated T cells-Phase I clinical trial. J. Immunother. (2001) 24(5):408-419.
143. ROSS S, LIU V, ABULAFIA R, HOGAN C, OSBAND M: Adoptive immunotherapy of hormone-refractory, stage D2 prostate cancer using ex vivo activated autologous T cells (autolymphocyte therapy): results from a pilot study. Biotechnol. Ther. (1993) 4(3-4):197-211.
144. THOMPSON JA, FIGLIN RA, SIFRI-STEELE C, BERENSON RJ, FROHLICH MW: A Phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma. Clin. Cancer Res. (2003) 9(10 Pt 1):3562-3570.
145. BUKOWSKI RM, SHARFMAN W, MURTHY S et al.: Clinical results and characterization of tumour-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma. Cancer Res. (1991) 51(16):4199-4205.
146. PEGGS KS, VERFUERTH S, PIZZEY A et al.: Adoptive cellular therapy for early cytomegalovirus infection after allogeneic stem-cell transplantation with virus-specific T-cell lines. Lancet (2003) 362(9393):1343-1344.